ETNB

89bio, Inc. [ETNB] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ETNB Stock Summary

Top 10 Correlated Stocks

ETNB

In the News

ETNB Financial details

Company Rating
-
Market Cap
918.18M
Income
-197.47M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-4.92
Forward P/E
-
PEG
-12.01
P/S
-
P/B
2.18
P/C
-
P/FCF
-8.72
Quick Ratio
17.78
Current Ratio
18.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.05
EPS next Y
-
EPS next Q
-
EPS this Y
-31.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
11.11%
-
-
-
-
SMA20
-0.1%
SMA50
51.42%
SMA100
-8.57%
Inst Own
-
Inst Trans
-
ROA
-40%
ROE
-50%
ROC
-0.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.575-22.93
52W High
-51%
52W Low
+79.67%
RSI
64.88
Rel Volume
0.71
Avg Volume
1.32M
Volume
934.66K
Perf Week
9.78%
Perf Month
17.69%
Perf Quarter
71.93%
Perf Half Y
45.68%
-
-
-
-
Beta
0.954
-
-
Volatility
0.33%, 0.3%
Prev Close
1.99%
Price
10.78
Change
7.26%

Something similar

Top by Market Cap
MSF.DE
V
META
0YXG.L
NVD.DE
Same Sector
2175.T
ESSI
CRY
8357.HK
SLV.WA
Top Correlated Stocks
VIR
NRIX
REPL
Similar Market Cap
NFI.TO
SNC.LS
VASWANI.NS
PCZ.DE
KSB.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 1.32M
  • Market Capitalization 918.18M
  • Employee 70
  • CEO Mr. Rohan Palekar
  • Headquarters San Francisco,CA,US
  • IPO Date 2019-11-11
  • Website https://www.89bio.com

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.